Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXN NYSE:CANF NASDAQ:GRDX NASDAQ:PMCB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$6.92+0.8%$6.64$5.41▼$12.05$8.51M1.515,728 shs1,789 shsCANFCan-Fite BioPharma$3.41+1.4%$3.44$2.83▼$23.40$2.23M1.09817,630 shs16,932 shsGRDXEntero Therapeutics$3.37+5.6%$2.33$1.06▼$5.84$11.17M1.38121,864 shs23,744 shsPMCBNuvilex$0.73+5.5%$0.72$0.63▼$1.51$7.87M0.46196,805 shs197,906 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-1.23%-4.94%+4.68%-13.10%-16.85%CANFCan-Fite BioPharma-4.27%+14.68%+15.07%-22.58%-84.86%GRDXEntero Therapeutics-6.73%+26.59%+52.63%+17.71%+318,999,900.00%PMCBNuvilex-8.06%-8.00%+6.40%-11.14%-37.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$6.92+0.8%$6.64$5.41▼$12.05$8.51M1.515,728 shs1,789 shsCANFCan-Fite BioPharma$3.41+1.4%$3.44$2.83▼$23.40$2.23M1.09817,630 shs16,932 shsGRDXEntero Therapeutics$3.37+5.6%$2.33$1.06▼$5.84$11.17M1.38121,864 shs23,744 shsPMCBNuvilex$0.73+5.5%$0.72$0.63▼$1.51$7.87M0.46196,805 shs197,906 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-1.23%-4.94%+4.68%-13.10%-16.85%CANFCan-Fite BioPharma-4.27%+14.68%+15.07%-22.58%-84.86%GRDXEntero Therapeutics-6.73%+26.59%+52.63%+17.71%+318,999,900.00%PMCBNuvilex-8.06%-8.00%+6.40%-11.14%-37.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 1.00SellN/AN/ACANFCan-Fite BioPharma 2.33Hold$42.501,147.80% UpsideGRDXEntero Therapeutics 0.00N/AN/AN/APMCBNuvilex 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CANF, ADXN, GRDX, and PMCB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026CANFCan-Fite BioPharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$2.50 ➝ $5.004/21/2026PMCBNuvilex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/8/2026ADXNAddex Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$460K18.49N/AN/A$10.37 per share0.67CANFCan-Fite BioPharma$405K5.51N/AN/A$1.76 per share1.94GRDXEntero Therapeutics$36.25K312.36N/AN/A$7.42 per share0.45PMCBNuvilexN/AN/AN/AN/A$7.56 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics$8.02M-$5.74N/AN/AN/AN/A-80.69%-69.69%5/25/2026 (Estimated)CANFCan-Fite BioPharma-$7.63M-$35.80N/AN/AN/AN/AN/AN/AN/AGRDXEntero Therapeutics-$6.39M-$1.69N/AN/AN/AN/A-60.44%-7.05%N/APMCBNuvilex$30.66M-$1.12N/AN/AN/AN/A2.13%1.69%7/1/2026 (Estimated)Latest CANF, ADXN, GRDX, and PMCB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2026Q4 2025GRDXEntero TherapeuticsN/A-$1.88N/A-$1.88N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/ACANFCan-Fite BioPharmaN/AN/AN/AN/AN/AGRDXEntero TherapeuticsN/AN/AN/AN/AN/APMCBNuvilexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A2.012.01CANFCan-Fite BioPharmaN/A2.93N/AGRDXEntero TherapeuticsN/A0.170.17PMCBNuvilexN/A12.3312.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%CANFCan-Fite BioPharma21.00%GRDXEntero Therapeutics12.30%PMCBNuvilex34.24%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%CANFCan-Fite BioPharma0.80%GRDXEntero Therapeutics0.75%PMCBNuvilex10.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.23 million1.05 millionNot OptionableCANFCan-Fite BioPharma8655,000N/ANot OptionableGRDXEntero Therapeutics93.36 million3.34 millionN/APMCBNuvilex410.74 million9.56 millionOptionableCANF, ADXN, GRDX, and PMCB HeadlinesRecent News About These CompaniesNuvilex (NASDAQ:PMCB) Trading Down 3.6% - Here's WhyMay 6, 2026 | americanbankingnews.comInsider Buying: Nuvilex (NASDAQ:PMCB) Director Acquires 20,000 Shares of StockJanuary 8, 2026 | insidertrades.comPharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency ApplicationsSeptember 2, 2025 | businesswire.comPharmaCyte Biotech, Inc. Announces Closing of $7 Million FinancingAugust 20, 2025 | businesswire.comPharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing InvestorsAugust 18, 2025 | businesswire.comMyMD Pharmaceuticals Secures Strategic InvestmentsMay 21, 2024 | businesswire.comPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseMay 21, 2024 | businesswire.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024December 18, 2023 | msn.comCompanies Like PharmaCyte Biotech (NASDAQ:PMCB) Are In A Position To Invest In GrowthDecember 15, 2023 | finance.yahoo.comPharmaCyte Biotech Inc PMCBDecember 5, 2023 | morningstar.comMWith biotech in a slump, the industry’s job market is upside downNovember 28, 2023 | statnews.comSThe return of biotech’s “bump factor” amid an economic downturnNovember 24, 2023 | statnews.comSPharmaCyte Biotech: Entry Into A Material Definitive Agreement, Other Events, Financial Statements And ExhibitsNovember 18, 2023 | cbonds.comCPharmaCyte Biotech Invests In Femasys - Quick FactsNovember 15, 2023 | markets.businessinsider.comFemasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte BiotechNovember 15, 2023 | finance.yahoo.comBiotech power broker John Maraganore offers advice to the next crop of entrepreneursOctober 23, 2023 | statnews.comSPharmaCyte completes tender offer to purchase sharesJune 15, 2023 | msn.comPharmaCyte Biotech Announces Final Results of Tender OfferJune 15, 2023 | finance.yahoo.comLos Angeles Biotech NewsJune 14, 2023 | bizjournals.comPharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per ShareMay 11, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCANF, ADXN, GRDX, and PMCB Company DescriptionsAddex Therapeutics NASDAQ:ADXN$6.92 +0.06 (+0.80%) As of 10:46 AM Eastern This is a fair market value price provided by Massive. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Can-Fite BioPharma NYSE:CANF$3.41 +0.05 (+1.37%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Entero Therapeutics NASDAQ:GRDX$3.37 +0.18 (+5.58%) As of 10:56 AM Eastern This is a fair market value price provided by Massive. Learn more.Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.Nuvilex NASDAQ:PMCB$0.73 +0.04 (+5.48%) As of 10:56 AM Eastern This is a fair market value price provided by Massive. Learn more.PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
